Barbara-Jean Bormann-Kennedy Sells 16,000 Shares of Xeris Biopharma (NASDAQ:XERS) Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director Barbara-Jean Bormann-Kennedy sold 16,000 shares of Xeris Biopharma stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $97,440.00. Following the completion of the transaction, the director owned 126,500 shares in the company, valued at approximately $770,385. This represents a 11.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

Xeris Biopharma stock opened at $6.18 on Friday. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.30 and a 12-month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The business’s 50-day moving average price is $6.10 and its two-hundred day moving average price is $6.59. The stock has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The firm had revenue of $83.13 million for the quarter, compared to analysts’ expectations of $79.83 million. As a group, analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

XERS has been the topic of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research report on Monday, March 2nd. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings cut Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Xeris Biopharma presently has a consensus rating of “Hold” and an average price target of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC bought a new stake in Xeris Biopharma during the 4th quarter worth $25,000. AlphaQuest LLC bought a new stake in Xeris Biopharma during the 3rd quarter worth $35,000. KBC Group NV bought a new stake in Xeris Biopharma during the 1st quarter worth $27,000. Caitong International Asset Management Co. Ltd grew its position in Xeris Biopharma by 9,276.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock worth $59,000 after acquiring an additional 7,421 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in Xeris Biopharma by 179.3% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 7,789 shares of the company’s stock worth $63,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.